Adverse Reactions to β 2-Agonist Bronchodilators

Lulich, Karmelo M.; Goldie, Roy G.; Ryan, Greg; Paterson, J. W.

doi:10.1007/bf03259844

Cited by 51 publications

(22 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since systemic β 2 -adrenoceptor stimulation may cause tachycardia and various metabolic effects,18 variables that reflect the effect of treatment on systemic β 2 -adrenoceptors are also presented, including plasma potassium, blood glucose, and the electrocardiogram (ECG)-derived QTc interval. Measurements of vital signs (pulse and blood pressure), ECG, plasma potassium, and blood glucose levels were made at baseline and at intervals during the treatment periods.…”

Section: Methodsmentioning

confidence: 99%

Safety of indacaterol in the treatment of patients with COPD

Donohue¹,

Singh²,

Kornmann³

et al. 2011

COPD

View full text Add to dashboard Cite

PurposePooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β2-agonist for chronic obstructive pulmonary disease (COPD).Patients and methodsData were pooled from clinical studies of 3–12 months’ duration in patients with moderate-to-severe COPD receiving double-blind indacaterol 75 μg (n = 449), 150 μg (n = 2611), 300 μg (n = 1157), or 600 μg once daily (n = 547); formoterol 12 μg twice daily (n = 556); salmeterol 50 μg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 μg once daily, given open label or blinded (n = 1214). Outcomes were adverse events, serious adverse events and deaths, plasma potassium, blood glucose, and QTc interval and vital signs.ResultsThe commonest adverse events with indacaterol were COPD worsening, nasopharyngitis, and headache; most cases were mild or moderate and incidence was generally similar to placebo and other active treatments. The risk of acute respiratory serious adverse events (leading to hospitalization, intubation, or death) was not significantly increased with any of the active treatments compared with placebo. COPD exacerbation rates (analyzed in the intent-to-treat population) were significantly reduced with all active treatments versus placebo. Hazard ratios versus placebo for major cardiovascular adverse events were <1 for all indacaterol doses. Notable values for vital signs and measures of systemic β2-adrenoceptor activity were rare with indacaterol. The number of deaths adjusted per patient-year was lower with indacaterol (all doses combined) than with placebo (relative risk 0.21 [95% confidence interval 0.07–0.660], P = 0.008).ConclusionIndacaterol has a good profile of safety and tolerability that is appropriate for the maintenance treatment of patients with COPD.

show abstract

Section: Methodsmentioning

confidence: 99%

Safety of indacaterol in the treatment of patients with COPD

Donohue¹,

Singh²,

Kornmann³

et al. 2011

COPD

View full text Add to dashboard Cite

show abstract

“…6 Generally, cardiac arrhythmias are not seen with selective b 2 -agonists. 11 Our case presented with sinus tachycardia, which resolved within 4 to 6 hours without any medication.…”

Section: Discussionmentioning

confidence: 94%

Hypoglycemia After Albuterol Overdose in a Pediatric Patient

Özdemir

Yılmaz²,

Duman³

et al. 2004

Pediatric Emergency Care

View full text Add to dashboard Cite

Albuterol overdose can lead to tachycardia, hypotension, tremor, hypokalemia, and hyperglycemia in children. Hypoglycemia had been previously reported in only one child. We describe a 3-year-old boy who ingested high-dose albuterol in this report. On arrival to the emergency department, the child was agitated and had noticeable restlessness, sinus tachycardia, mild hypokalemia (3.2 mEq/L), and hyperglycemia (187 mg/dL). Activated charcoal and intravenous hydration were given, and electrocardiogram monitoring was performed. Sinus tachycardia resolved within 4 to 6 hours. Hypoglycemia (45 mg/dL) was identified 4 hours after admission. The child recovered uneventfully within 24 hours with glucose replacement. This case suggests that hypoglycemia could be a late complication of acute albuterol overdose; thus, the period of observation should be extended in these cases.

show abstract

“…Cardiac side effects are more common following i.v. administration of ␤-adrenoceptor agonists (83). Cardiac arrhythmias are uncommon during inhalation of ␤ 2 -adrenoceptor agonists at recommended dose levels.…”

Section: General Side Effectsmentioning

confidence: 99%

“…Laursen et al (77) observed an increased incidence of ventricular ectopic and supraventricular beats in patients receiving both types of drugs. ␤ 2 -Adrenoceptor agonists produce no serious central nervous system side effects (83). Nervousness may occur after oral or aerosol (high dose) administration (45,90).…”

Section: General Side Effectsmentioning

confidence: 99%

Fenoterol: Pharmacology and Clinical Use

Ch¹

1999

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Adverse Reactions to β 2-Agonist Bronchodilators

Cited by 51 publications

References 88 publications

Safety of indacaterol in the treatment of patients with COPD

Safety of indacaterol in the treatment of patients with COPD

Hypoglycemia After Albuterol Overdose in a Pediatric Patient

Fenoterol: Pharmacology and Clinical Use

Contact Info

Product

Resources

About